Table 2 Number of patients, used cell type, administration route, and cell dosage strategies of selected studies
From: Cell therapies for autism spectrum disorder: a systematic review of clinical applications
Studies | Patients enrolled | Cell type | Route | Dosage (avg.) | Summary of the outcome | |
|---|---|---|---|---|---|---|
Treat | Cont | |||||
Bansal et al. [7] | 10 | - | Auto. BM-MNC | Intrathecal | Not mentioned | Improvement |
Sharma et al. [78] | 32 | - | Auto. BM-MNC | Intrathecal | 8.19 × 107 | Significant improvement |
Nguyen Thanh et al. [61] | 30 | - | Auto. BM-MNC | Intrathecal | 1st: 42.3 × 106/kg MNC (2.6 × 106 CD34 +) | Significant improvement |
2nd: 40.9 × 106/kg MNC (2.1 × 106 CD34 +) | ||||||
Chez et al. [15] | 15 | 15 | Auto. CB | Intravenous | 16.16 × 106 TNC /kg | No change |
Dawson et al. [20] | 23 | - | Auto. CB | Intravenous | 2.6 × 107 TNC /kg | Significant improvement |
Dawson et al. [21] | 119 | 61 | Auto./Allo. CB | Intravenous |  > 2.5 × 107 TNC/kg | No change |
Simhal et al. [81] | 110 | 55 | Auto./Allo. CB | Intravenous | 2.5 × 107 TNC /kg | No change |
Sharifzadeh et al. [77] | 18 | 18 | Auto. BM-MSC | Intrathecal | 1st: 0.5—1 × 108 | No change |
2nd: 0.3—0.5 × 108 | ||||||
Sun et al. [87] | 12 | - | Allo. UC-MSC | Intravenous | 1st: 2 × 106/kg | Improvement |
2nd: 2 × 106/kg | ||||||
3rd: 2 × 106/kg | ||||||
Lv et al. [51] | 23 | 14 | Allo. CB-TNC/Allo. CB-TNC + Allo. UC-MSC | CB-TNC group: 1st IV, 2nd–4th IT Combination group: 1st–2nd IV-IT CB-TNC, 3rd–4th IT UC-MSC | 1st: 2 × 106 CB-TNC/kg + 1 × 106 UC-MSC/kg | Significant improvement |
2nd: 2 × 106 CB-TNC/kg + 1 × 106 UC-MSC/kg | ||||||
3rd: 2 × 106 CB-TNC/kg + 1 × 106 UC-MSC/kg | ||||||
4th: 2 × 106 CB-TNC/kg + 1 × 106 UC-MSC/kg | ||||||
Bradstreet et al. [10] | 45 | - | HSC and FSC | Intravenous/subcutaneous | 1st: 48 × 106 TNC | Significant improvement |
2nd: 18.44 × 106 FSC | ||||||